Physician
Hematology
Dr. Denise A. Yardley, MD
|
|
Give Review
Doctor Denise A. Yardley, MD is an expert in the field of Hematology. She attended University of Texas Southwestern Medical School. She received 1 awards: "Redbook Magazine: Top Breast Cancer Doctors". Denise Yardley has written publications. She has 83 publications published with PubMed. The lastest publication is: 'Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.' Denise A. Yardley accepts Medicare payments and is listed with Medicare.gov.
Publications
- Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
- Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase...
- Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capec...
- A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response ...
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
- Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate c...
- Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics.
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer.
- Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial.
- Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.
- Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.
- Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
- Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.
- Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
- Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- nab-Paclitaxel mechanisms of action and delivery.
- Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer.
- Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer.
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estro...
- Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions.
- Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prio...
- Updates in the treatment of basal/triple-negative breast cancer.
- Phase II open-label study of sunitinib in patients with advanced breast cancer.
- A Phase I Trial of Vatalanib (PTK/ZK) in Combination With Bevacizumab in Patients With Refractory and/or Advanced Malignancies.
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER.
- Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology...
- A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
- Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
- RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth ...
- A pilot study of adjuvant Doxorubicin and cyclophosphamide followed by Paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
- A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors.
- Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
- A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced ...
- A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
- Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety.
- Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents.
- Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.
- Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction.
- Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
- Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer.
- A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer.
- Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
- Proactive management of adverse events maintains the clinical benefit of ixabepilone.
- Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
- Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
- A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
- A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high...
- Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Netw...
- Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial.
- Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer.
- Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
- Gemcitabine plus paclitaxel in breast cancer.
- Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
- Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
- Integrating gemcitabine into breast cancer therapy.
- Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer.
- Gemcitabine and taxanes as a new standard of care in breast cancer.
- Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase ...
- Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
- Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.
- Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced ...
- Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents.
- Drug resistance and the role of combination chemotherapy in improving patient outcomes.
- First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER.
- Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer.
- Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes.
- A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage...
- Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
- Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
- Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
- Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck.
- In pursuit of the prevention of breast cancer.
- Clinical and laboratory features and sequelae of deficiency of folic acid (folate) and vitamin B12 (cobalamin) in pregnancy and gynecology.
- Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers.
- Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
- Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
- A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
- A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer.
- A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.
- A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.
Schools
Medical College Of Georgia School Of Medicine
University Tx Southwestern Med School
Procedures Preformed
- Thoracentesis
Doctors Specialties
- Hematology
- Medical Oncology
Accepted Insurances
Awards
- Redbook Magazine: Top Breast Cancer Doctors
Education
-
University of Texas Southwestern Medical School -
Medical College of Georgia School of Medicine
Drug Facts
| NPI NUMBER | 1801829114 | |
| NPPES Provider LastName | YARDLEY | |
| NPPES Provider FirstName | DENISE | |
| NPPES Provider ZIPCode | 372031632 | |
| NPPES Provider State | TN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 865.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 1.27 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1801829114 |
| Last Name Of The Provider | YARDLEY |
| First Name Of The Provider | DENISE |
| View All |
Similar Doctors
|
Dr. Karl M. Rogers, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen A. Strickland Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven N. Wolff, MD |
|
Dr. Jeffery F. Patton, MD |
|
|
Dr. Johanna Bendell, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Christina L. Derleth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacey A. Goodman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jia Bi, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Barbara A. Murphy, MD |
|
|
Dr. Robert F. Cornell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sandra S. Zinkel, MD
This Doctor is OpenDoctor Recommended.
|